C. A. Lindquist

University of California, Berkeley

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Joseph R. Bertino

Rutgers Cancer Institute of New Jersey

Ed Cadman

University of California, San Francisco

Barbara A. Moroson

Yale University

Daniella Hirschfeld

Utah State University

Susanne Ziegler

RWTH Aachen University

W. M. Kaula

University of California, Los Angeles

Vatsala Gupta

Virginia Commonwealth University

Roland T. Skeel

University of Toledo Medical Center

F. J. Cook

Griffith University

John D. Lenters

University of Michigan–Ann Arbor

Cooperative Institutions

Yale University

American Cancer Society

University of California, Berkeley

Utah State University

Berkeley College

National Academies of Sciences, Engineering, and Medicine

University of Colorado Boulder

Rutgers, The State University of New Jersey

Rutgers Cancer Institute of New Jersey

Johnson University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

A fluorometric assay for dihydrofolate reductase

Analytical Biochemistry (1977)

C. A. Lindquist Ed Cadman Joseph R. Bertino

Dihydrofolate reductase

10.1016/0003-2697(77)90504-8

Cite

Citations (7)

A sampling window test method for evaluation of phase encoded recorder systems

Rundbrief Der Gi-fachgruppe 5.10 Informationssystem-architekturen (1976)

Jesse Lerma C. A. Lindquist

Source

Cite

Citations (0)

Clinical Aspects of Resistance to Antineoplastic Agents

Chemotherapy (1977)

Roland T. Skeel C. A. Lindquist

Were it not for the resistance of human tumors to antineoplastic agents, disseminated cancer would not be a clinical problem, and in fact surgery and radiotherapy would be passé. All too familiar to the layperson, physician, and biomedical scientist, however, is the fact that most disseminated cancers respond little, if at all, to systemic chemotherapy, and among those cancers that are initially responsive, the duration of clinical benefit is more often marked by months than years. Thus, those whose aim is to discover the means for successfully treating cancers have had to contend with drug resistance.

Antineoplastic Drugs

10.1007/978-1-4615-6628-1_4

Cite

Citations (4)

Rising Coastal Groundwater as a Result of Sea‐Level Rise Will Influence Contaminated Coastal Sites and Underground Infrastructure

Earth s Future (2023)

Kristina E. Hill Daniella Hirschfeld C. A. Lindquist F. J. Cook Scott D. Warner

Abstract Sea‐level rise (SLR) will cause coastal groundwater to rise in many coastal urban environments. Inundation of contaminated soils by groundwater rise (GWR) will alter the physical, biological, and geochemical conditions that influence the fate and transport of existing contaminants. These transformed products can be more toxic and/or more mobile under future conditions driven by SLR and GWR. We reviewed the vulnerability of contaminated sites to GWR in a US national database and in a case comparison with the San Francisco Bay region to estimate the risk of rising groundwater to human and ecosystem health. The results show that 326 sites in the US Superfund program may be vulnerable to changes in groundwater depth or flow direction as a result of SLR, representing 18.1 million hectares of contaminated land. In the San Francisco Bay Area, we found that GWR is predicted to impact twice as much land area as inundation from SLR, and 5,282 additional state‐managed sites of contamination may be vulnerable to inundation from GWR in a 1.0 m SLR scenario. Increases of only a few centimeters of elevation can mobilize soil contaminants, alter flow directions in a heterogeneous urban environment with underground pipes and utility trenches, and result in new exposure pathways. Pumping for flood protection will elevate the saltwater interface, changing groundwater salinity and mobilizing metals in soil. Socially vulnerable communities are disproportionately exposed to this risk at both the national scale and in a regional comparison with the San Francisco Bay Area.

10.1029/2023ef003825

Cite

Citations (9)

Schedule-dependent antitumor effects of methotrexate and 5-fluorouracil.

PubMed (1977)

Joseph R. Bertino Wendy L. Sawicki C. A. Lindquist Vatsala Gupta

The antitumor effects of methotrexate with 5-fluorouracil against the Sarcoma 180 mouse tumor model were found to be schedule dependent. Pretreatment of tumor-bearing animals with methotrexate significantly enhanced the antitumor activity of the combination relative to simultaneous treatment or to those with methotrexate following 5-fluorouracil. These studies indirectly support the hypothesis that methotrexate pretreatment with 5-fluorouracil is synergistic by increasing the amount of thymidylate synthetase bound to the active metabolite of 5-fluorouracil.

Antifolate

Source

Cite

Citations (191)

Enhanced intracellular cytosine arabinoside uptake following mtx pretreatment. A biochemical study of human leukemia and experimental tumor cells. Abstr.

Ed Cadman C. A. Lindquist F Eiferman

Cytosine

Source

Cite

Citations (1)

A methotrexate resistant subline of l1210 characterized by impaired transport of methotrexate, but not 5-methyl tetra- hydrofolate. Abstr.

Proceedings of the American Association for Cancer Research (1978)